Opinion|Videos|August 5, 2024
Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment
A panel of experts discuss combination regimens with BTK inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What emerging evidence is there for combination therapies of BTK inhibitors with new and existing therapies to enhance treatment efficacy in CLL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
How Do GLP-1 Agonists Fit Into Stroke Care?
3
Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD
4
Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making
5
